APLT News and Press, Applied Therapeutics Inc. From 11/12/20

Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony ...

Applied Therapeutics (APLT): Q3 GAAP EPS of -$1.33 misses by $0.21.Cash, equivalents and short-term investments totaled $116.5M.Shares +1.03% PM.Press Release For further details see: Applied Therapeutics EPS misses by $0.21

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics) On track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half o...

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today  presentation ...

Gainers: Miragen Therapeutics (MGEN) +86%, Titan Pharmaceuticals (TTNP) +62%, Community Health Systems (CYH) +35%, Scholar Rock Holding (SRRK) +7%, Rafael Holdings (RFL) +7%.Losers: Neovasc (NVCN) -44%, Akerna (KERN) -19%, Tiziana Li...

Gainers: [[SRRK]] +23.7%. [[SYNL]] +12.3%. [[CYH]] +11.6%. [[FSLR]] +8.8%. [[MSTR]] +7.1%.Losers: [[KTCC]] -12.8%. [[SUM]] -8.7%. [[RCUS]] -8.3%. [[BGFV]] -6.0%. [[APLT]] -5.8%. For further details see: SRRK, SYNL, KTCC and SUM among after-hours movers

The stock market is undergoing some distribution. During these periods of time, stock selection is even more important. The POWR Ratings can help you identify ones that are performing well and avoid those with poor prospects. Here are five stocks the POWR Ratings have recently downgraded. ...

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will p...

The FDA grants Pediatric Rare Disease and Orphan Designation to Applied Therapeutic's (APLT) +3.7% AT-007 for treatment of PMM2-CDG, a disease caused by deficiency in the critical enzyme phosphomannomutase-2, required for systemic glycosylation of proteins.AT-007, a novel ...

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the ...